68Ga-Autoclabeling of DOTA-TATE and DOTA-NOC

Applied Radiation and Isotopes

Volumn 70, Issue 6, 2012, Pages 980-983

  Blom, Elisabeth ^a   Koziorowski, Jacek ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

68Ga; DOTA NOC; DOTA TATE

Indexed keywords

ACETATE BUFFERS; DOTA-NOC; DOTA-TATE; NEUROENDOCRINE TUMORS; OSMOLALITY; SINGLE-STEP; SOMATOSTATIN RECEPTORS; STEAM STERILIZATION;

DEGRADATION; PEPTIDES; POSITRON EMISSION TOMOGRAPHY; STERILIZATION (CLEANING);

GALLIUM;

ACETIC ACID; BUFFER; ENDOTOXIN; GALLIUM 68; RADIOISOTOPE; TETRAXETAN 3 (1 NAPHTHALENYL)ALANINE OCTREOTIDE; TETRAXETAN OCTREOTATE[3 TYROSINE]; UNCLASSIFIED DRUG; 68GA DOTANOC; 68GA DOTATATE; 68GA-DOTANOC; 68GA-DOTATATE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STABILITY; HEATING; HIGH TEMPERATURE; ISOTOPE ANALYSIS; ISOTOPE LABELING; OSMOLALITY; PH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DECAY; ISOLATION AND PURIFICATION; METHODOLOGY; ROBOTICS; SYNTHESIS; WATER VAPOR;

CONTRAST MEDIA; ISOTOPE LABELING; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; ROBOTICS; STEAM;

EID: 84860179642     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2012.03.032     Document Type: Article

References (20)

1. Ando A., Ando I., Hiraki T., Hisada K. Relation between the location of elements in the periodic table and various organ-uptake rates. Nucl. Med. Biol 1989, 16:57-80.
2. Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:982-993.
3. Breeman W.A.P., Verbruggen A.M. The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?. Eur. J. Nucl. Med. Mol. Imaging 2008, 34:978-981.
4. CPMP/QWP/3015/99, 2001. 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003361.pdf〉.
5. European Pharmacopoeia 7.0, 5.1.1, 2010. Methods of preparation of sterile products.
6. European Pharmacopoeia 7.0, 5.1.2, 2010. Biological indicators of sterilisation.
7. European Pharmacopoeia Draft Monograph proposal, 2011a. Gallium (68Ga) chloride solution for radiolabelling. PA/PH/Exp. 14/T (08) 21 ANP. http://www.eanm.org/committees/radiopharmacy/Gallium_233E.pdf?PHPSESSID=06a4ca4cfb4fc26b12455abcfb77dd69.
8. European Pharmacopoeia Draft Monograph proposal., 2011b. Gallium (68Ga) Edotreotide Injection. PA/PH/Exp. 14/T (07) 12 ANP 2R. http://www.eanm.org/committees/radiopharmacy/Gallium2482E.pdf.
9. Forrer F., Valkema R., Kwekkeboom D.J., de Jong M., Krenning E.P. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21:111-129.
10. Gabriel M., Decristoforo C., Kendler D., Dobrozemsky G., Heute D., Uprimny C., et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 2007, 48:508-518.
11. Hofmann M., Weitzel T., Krause T. Ga-68-DOTATOC: Feasibility of high throughput screening by small animal PET using a clinical highresolution PET/CT scanner. Nucl. Instrum. Methods Phys. Res. Sec. A: Accel., Spectrom., Detectors Assoc Equip. 2006, 569:522-524.
12. 68Ga generator. J. Lab. Compd. Radiopharm 2009, 52:S116.
13. Kowalski J., Henze M., Schuhmacher J., Macke H.R., Hofmann M., Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 2003, 5:42-48.
14. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A.P., Kooij P.P.M., Oei H.Y., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phel] - and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993, 20:716-731.
15. Reubi J.C., Schär J.-C., Waser B., Wenger S., Heppeler A., Schmitt J.S., Mäcke H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 2000, 27:273-282.
16. Rösch F., Knapp F.F. Radionuclide generators. Handbook of Nuclear Chemistry 2003, vol. 4:81-118. Kluwer Academic Publishers, Dordrecht, The Netherlands.
17. Roesch F., Riss P.J. The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr. Top. Med. Chem. 2010, 10:1633-1668.
18. Velikyan I., Sundin A., Eriksson B., Lundqvist H., Sörensen J., Bergström M., Långström B. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl. Med. Biol. 2010, 37:265-275.
19. Waldherr C., Pless M., Maecke H.R., Schumacher T., Crazzolara A., Nitzsche E.U., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4GBq (90)Y-DOTATOC. J. Nucl. Med. 2002, 43:610-616.
20. Wild D., Schmitt J.S., Ginj M., Macke H.R., Bernard B.F., Krenning E., de Jong M., Wenger S., Reubi J.-S. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1338-1347.